Please ensure Javascript is enabled for purposes of website accessibility

Addus Homecare Corp (ADUS) Q2 2021 Earnings Call Transcript

By Motley Fool Transcribers – Aug 3, 2021 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ADUS earnings call for the period ending June 30, 2021.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Addus Homecare Corp (ADUS -0.80%)
Q2 2021 Earnings Call
Aug 3, 2021, 9:00 a.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Good day, and thank you for standing by. Welcome to the Addus HomeCare Corp. Second Quarter 2021 Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to Dru Anderson. Please go ahead.

10 stocks we like better than Addus HomeCare
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

They just revealed what they believe are the ten best stocks for investors to buy right now... and Addus HomeCare wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Dru Anderson -- Corporate Communications

Good morning, and welcome to the Addus HomeCare Corporation Second Quarter 2021 Earnings Conference Call. Today's call is being recorded. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on by going to the company's website and reviewing yesterday's news release.

This conference call may also contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Addus' expected quarterly and annual financial performance for 2021 or beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, discussions of forecasts, estimates, targets, plans, beliefs, expectations and the like are intended to identify forward-looking statements.

You are hereby cautioned that these statements may be affected by important factors, among others, set forth in Addus' filings with the Securities and Exchange Commission and in its second quarter 2021 news release. Consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

At this time, I would like to turn the call over to the company's Chairman and Chief Executive Officer, Mr. Dirk Allison. Please go ahead, sir.

R. Dirk Allison -- President and Chief Executive Officer

Thank you, Dru. Good morning, and thank you for joining us for our 2021 second quarter earnings call. With me today are Brian Poff, our Chief Financial Officer; and Brad Bickham, our President and Chief Operating Officer. As usual, I will begin with some overall comments, and then Brian will discuss the second quarter results in more detail. Following our comments, we would be happy to respond to any questions. Yesterday, we announced our financial results for the second quarter of 2021.

We continue to be proud of our solid operating performance as we have started to see our markets return to a more normal environment. Our revenue for the second quarter of 2021 was $217.9 million as compared to $184.6 million for the second quarter of 2020, an increase of 18.1%. Adjusted earnings per diluted share for the second quarter of 2021 was $0.90 as compared to $0.73 for the second quarter of 2020, an increase of 23.3%. Our adjusted EBITDA for the second quarter of 2021 was $24.3 million as compared to $18.7 million for the second quarter of 2020, an increase of 30.1%.

During the second quarter, we started to see the positive effect of the $350 billion in State aid, which came from the Federal Stimulus plan. Our states have done a nice job in maintaining or, in some cases, increasing receivable payments to Addus, leading to a very nice cash flow for the quarter and a cash balance at June 30 of approximately $139 million. Our largest state, Illinois, as scheduled, increased their statewide reimbursement rate on April one to cover the minimum wage increase, which was effective in Chicago on July one of last year. In addition, the state made this rate increase retroactive to January 1, 2021, for the approximate 60% of our business, which is reimbursed directly by the state as opposed to -- through MCOs.

As we discussed on previous earnings calls, the minimum wage increases planned for Chicago have now come to an end. The final Chicago minimum wage increase of $1 per hour, which takes the city's minimum wage to $15 was effective on July one 2021. In the state of Illinois budget for fiscal 2022, the state has budgeted to offset this recent July 1, 2021 Chicago minimum wage increase with an additional statewide reimbursement rate increase, which was originally to be effective January 1, 2022.

However, with the receipt of the additional 10% FMAP which is currently in place from the earlier mentioned stimulus bill, the state has now requested approval from the federal government to accelerate this rate increase by two months, making it effective on November 1, 2021. We are grateful for this consideration by the state and expect approval from the federal government in the next few weeks. We are hopeful that other states will consider similar requests for use of the additional federal funding.

As for our New York CDPAP business, which was discussed on our last call, we continue to await word on our formal protest concerning our non-award in the provider selection process for the CDPAP program. We anticipate hearing something from the state concerning this protest over the next few months. In the meantime, we did file our response to the state survey, which was created by the state to consider additional awards to providers for this program. While we have no knowledge of when there will be a decision on additional awards, the state recently provided a time line stating that new contracts for winners of this program will not be effective until November 1, 2021, at the earliest.

We continue to believe any changes that will affect Addus will most likely be in 2022. With most of our locations returning to a more normal operating environment, we are starting to see improvements in our same-store revenue. Our same-store revenue growth for our personal care segment increased as expected for the past quarter, partially due to the Illinois rate increase, but also due to increasing volumes. For the second quarter of 2021, our personal care same-store revenue growth was [Technical Issues] when compared to the second quarter of 2020. Our previously announced same-store revenue growth for personal care for our first quarter of this year was 2.4%. However, adjust for the recently announced Illinois retro payment for our direct state business, we would have experienced a 4.4% growth rate, which is the upper end of our normal 3% to 5% target.

We continue to be very pleased with the performance of this segment of our business in spite of the challenges we have faced over the last several quarters due to the pandemic. Our ability to hire caregivers in our personal care segment is also seeing improvements. Our personal caregiver hires in our second quarter were approximately equal to the rate we were able to hire in our previous quarter, which was a marked improvement over the last six months of 2020.

While hiring continues to be a challenge for our team, we are pleased that we are making progress in this area, with June being our highest hiring quarter month so far in 2021. As for our home health segment, our same-store revenue growth was 24.7% as compared to the second quarter of 2020 and up from the flat year-over-year growth we saw in the first quarter of this year. Since the beginning of 2021, our home health admissions have increased steadily with this favorable trend continuing throughout our second quarter and into July. A few weeks ago, we announced the pending acquisition of Armada Home Health and Hospice. Effective August 1, we closed on this transaction, which more than doubled our revenues from our home health segment.

This acquisition helps to give us the increased coverage for our home health to capitalize on our strategy of fully covering the State of New Mexico with all three levels of home care that we offer. We are excited about the Armada team joining our company, and I want to welcome each of them to Addus. For the second quarter of 2021, our hospice same-store revenue decreased 8.4% and similar to the first quarter of this year. However, we did see the same-store admission grow 12% over the second quarter of 2020, which should lead to higher census as the year progresses.

While ADC has not yet returned to where we would like it to be, we did see nice growth in our ADC during July. At the end of July, our census was over 2,550, which is the highest census we have seen in many months. Our median length of stay, which was 17 days in our first quarter of 2021 continues to improve with a medium length of stay in our second quarter of 2021, increasing to 19 days and our July medium length of stay reaching 21 days. Our Queen City operation in Ohio has grown from 890 at the time of acquisition to over 1,000 in July, maintaining the positive experienced -- the positive momentum experienced in 2021.

We are also excited to see our other hospice markets, including New Mexico continue to make progress toward our growth expectations. As you saw with our Armada acquisition, we continue to focus on acquisitions, which meet our goal of creating multiple markets of scale where we provide all three levels of HomeCare. For 2021, our focus has primarily been in the personal care and home health segments of our business.

However, we will continue to look at strategic opportunities in all three segments. As we announced yesterday, we closed on a new $600 million revolving credit facility. We are excited to complete this process and are grateful to our bank partners who stepped forward to support Addus. With our continued strong liquidity position, we have the ability and the desire to close additional strategic acquisitions during the next several months. With the increasing focus on HomeCare services as a result of the pandemic, the acquisition landscape remains very competitive, particularly for clinical service providers of scale.

As we have demonstrated over the past few years, we will continue to focus on our strategy to pursue transactions that are accretive and that will bring revenue and operating synergies to Addus. While conditions related to the COVID-19 pandemic have improved in recent months in the United States, as facts and nations have become more widely available, it continues to be impossible to predict the effect and ultimate impact of this pandemic on Addus as the situation continues to [evolve.]

Our team is continuing to monitor the COVID Delta variant and the recent uptick in COVID cases. This past 15 months have shown the value of taking care of elderly and disabled consumers and patients in their homes. And as such, we have invested in planning, preparation and materials to assist us in fulfilling our role as we monitor these developments. We firmly believe that the pandemic has raised awareness for the value of our industry -- the value our industry provides and will continue to be an opportunity for growth for our company.

However, our operations and resulting growth are dependent on our dedicated caregivers who work so hard providing outstanding care and support to our consumers, patients and their families. I am thankful for each of our team members, and I'm proud of the job they have done in the past 15 months and continue to do each day. It is important that each of us focus on achieving our mission by putting our patients first.

With that, let me turn the call over to Brian.

Brian Poff -- Executive Vice President and Chief Financial Officer

Thank you, Dirk, and good morning, everyone. Addus had another strong financial performance in the second quarter of 2021, with consistent profitable growth and continued improvement in volume trends across all of our operating segments, personal care and home health exceeding our organic growth targets, our hospice segment experiencing solid emissions and sequential growth in census.

As Dirk noted, total net service revenues for the second quarter were $217.9 million. The revenue breakdown is as follows: Personal care revenues were $176.3 million or 80.9% of revenue. Hospice care revenues were $36.9 million or 16.9% of revenue. These results include the addition of Queen City hospice in Ohio, which closed at the end of 2020. Home health revenues were $4.7 million or 2.2% of revenue. Included in our results are the incremental benefits of the four acquisitions we completed in the second half of 2020, three in personal care and one in hospice, which totaled approximately $84 million in annualized revenue.

We also closed our Armada Home Health and Hospice acquisition in New Mexico on August 1, with $23 million in annualized revenues, and look forward to completing additional acquisitions that meet our strategic criteria. Our gross margin percentage was 31.6%, an increase from 29.8% for the second quarter last year, largely attributable to the higher mix of clinical services and up from 29.8% sequentially from the first quarter as we saw the positive impact of the most recent reimbursement increase in Illinois. Similar to our recent past experience, we anticipate our gross margin to be negatively impacted by approximately 40 basis points in the third quarter by the last scheduled increase in Chicago minimum wage that was effective on July 1, with the offsetting state reimbursement increase currently scheduled for January 1, 2022.

We are hopeful, however, that the state's request for federal approval to accelerate the statewide reimbursement increase to November one will be granted. G&A expense was 22.1% of revenue, a decrease from 23% in the second quarter last year. Adjusted G&A expense was 20% of revenue, essentially flat from the same period last year and a decrease of 40 basis points sequentially from the first quarter. The company's adjusted EBITDA increased to $24.3 million for the second quarter of 2021 compared to $18.7 million in the second quarter of 2020.

Adjusted EBITDA margin was 11.2% compared with 10.1% for the second quarter of 2020, an increase sequentially from 9.4% in the first quarter. Adjusted net income per diluted share was $0.90. The adjusted per share results for the second quarter of 2021 excludes the following: The impact of the retroactive Illinois rate increase of $0.07, acquisition and de novo expenses of $0.11, restructuring and other costs of $0.02 and noncash stock-based compensation of $0.12.

Our adjusted per share results for the second quarter of 2020 excluded loss on sale of assets of $0.02, COVID-19 expenses net of $0.01, acquisition expenses of $0.09, restructuring and other costs of $0.12 and noncash stock-based compensation of $0.06. Our effective tax rate for the second quarter of 2021 was 26.7%, within the range of our expectation. For the full year 2021, we expect a tax rate in the mid-20% range. DSOs were [56.9 days] at the end of the second quarter of 2021 compared with 60.8 days at the end of the first quarter. As expected, we saw strong collections from the Illinois Department of Aging with their DSO at 42.7 days at the end of the second quarter of 2021.

Our second quarter net cash provided by operations totaled $15 million. However, during the quarter, we also utilized approximately $12.3 million in government stimulus funds that we had previously received, which without Addus making these payments, our cash flow from operations would have been $27.3 million. At June 30, 2021, the company had cash on hand of $139.4 million, $196.1 million of bank debt and $112.8 million in availability under our revolver.

As noted in our press release, we executed on a new senior secured credit facility effective July 30, 2021, that expands our revolving credit facility to $600 million from $300 million with no term loans. The agreement has an accordion feature that enables the credit facility to be expanded by an incremental $125 million for funding acquisitions. The maturity of the new facility has also been extended by an additional three years to July 2026. The Capital One, National Association acted as a lead agent for our bank group, and we appreciate the continued support of all of our lenders.

With this new facility in place, our current availability under our revolver increased immediately by an additional $19 million and further enhances our well-capitalized balance sheet, allowing us to continue to pursue our acquisition strategy. We feel confident Addus is well positioned to continue to be one of the leaders in the industry, and we are looking forward to our opportunities for the remainder of 2021 and beyond. This concludes our prepared comments this morning, and thank you for being with us.

I'll now ask the operator to please open the line for your questions.

Questions and Answers:


[Operator Instructions] Your first question comes from the line of Matt Borsch with BMO Capital Markets.

Matt Borsch -- BMO Capital Markets -- Analyst

Yes. Good morning. I was hoping maybe you could talk a little bit more about the competition for acquisitions. I think it was most intense in the hospice area previously. And so now perhaps it's most intense on the home health side. Can you characterize who your -- what types of organizations you're competing against the most? And if I could ask this question also can you reveal if there have been inquiries about Addus being acquired by some other organizations?

R. Dirk Allison -- President and Chief Executive Officer

Well, Matt, you want to start it off with a hard one today, didn't you? As we look at acquisitions, certainly, this year, as we said earlier, we've been focused most on personal care in home health, although we will look at hospice if it's strategic. And one of the things we found, there are a number of companies out there that are looking for deals.

If you go back over the last few months, you've seen a lot of our larger competitors have acquired companies. There's also been private equity firms out there that acquired companies. And so as we look at it, this is a market that's going -- is attractive. The pandemic has proven that home care makes a lot of sense. And I think a lot of people are wanting to get into this business or get bigger.

I think the one thing that I want to emphasize is that we are going to maintain our discipline to be strategic and to look at deals that are accretive to our company. We will constantly look at opportunities in those major markets that we have talked about in the past, the five or six markets where we want to continue to build like New Mexico, where we want to continue to build three levels of care.

And we will be obviously aggressive in those markets if it's a very strategic acquisition. But we also realize that some people are willing to pay more than we are. And at that point, we want to maintain our discipline. As it relates to your last part of the question, Addus is not for sale, hasn't been for sale, and we are not in any way talking with anybody about that.

Matt Borsch -- BMO Capital Markets -- Analyst

Alright. Thank you.


Your next question comes from the line of Scott Fidel with Stephens.

Scott Fidel -- Stephens -- Analyst

Hi. Thanks. Good morning, everyone. First question, just appreciate the update around some of the enhanced FMAP funds, it looks like visibility is starting to come in, in terms of what you called out, with potentially a faster update in November on the Illinois rate increase that was scheduled for January.

Just interested, as you're looking across the other states as well in terms of your other key personal care markets. Just any type of visibility or indications that you're getting at this point in terms of how some of those enhanced FMAP funds from ARP may start to flow through into the personal care business?

R. Dirk Allison -- President and Chief Executive Officer

Yes. Hi. I think what we're seeing -- and again, a lot of states are still in the planning stage. I think there's kind of an underlying thing that most states are not trying to add long-term -- new long-term plans that would require funding once the FMAP dollars go away. As you know, the FMAP dollrs are a match for a year.

The states have three years of which to use those funds. States, I think, are doing what -- looking like what Illinois did. Illinois already had a rate increase plan, and what they decided to do was use partial funds to move that forward 60 days, I think you will see things along those lines being considered in other states. But at this point in time, there's no concrete plans that we're aware of in other states that we could talk to you about today.

Scott Fidel -- Stephens -- Analyst

Okay. Then next question, just, Brian, I know you called out the expected impact sequentially in 3Q just from the Chicago minimum wage going into effect. It would be helpful if you maybe wanted to just bring it up to the higher level in terms of thinking on the EBITDA margin progression for 3Q and then into 4Q. And then how that may shake out when looking at the full year now after having reported the second quarter results, how you're thinking about full year EBITDA margin against that long-term 10% plus target.

Brian Poff -- Executive Vice President and Chief Financial Officer

Yes, Scott. I think just looking back real quickly. I mean 2020 was the first year that we had a full year over 10%, which we had talked about a few years ago as kind of being our target. I think we're pretty happy getting into the second quarter of this year and being ahead of 11%. We usually have a lower first quarter as we saw as a result of payroll taxes and the like that reset. So we're seeing some relief there, additional incremental leverage off of our clinical business.

So adding Armada is definitely going to help from a margin perspective in Q3 to help offset a little bit of what we'll see from the headwind in the Illinois minimum wage increase in Chicago. If they're able to pull forward the statewide increase to November 1, I think we'll see a nice impact in Q4. I think as you guys are aware, typically, with that increase, we see $20-plus million in new revenue statewide, with corresponding cost, but a nice margin attached to it. So I think our thought process looking at the full year of 2021 compared to 2020, we definitely see ourselves coming in with a higher bottom line margin percentage than we saw last year on continued growth and continued expansion.

So with our strategy that we have of adding clinical services where it makes sense strategically, continue to grow and get leverage off of our G&A, I think we would expect to see continued expansion on that bottom line as well into the future.

Scott Fidel -- Stephens -- Analyst

Got it. If I could just slip a follow-up on that on the EBITDA margin side. Just as we now roll in the Armada deal, which closed into the model. Any color you could give us on -- I know you talked about that being immediately accretive financially. But how we should think about the EBITDA margin profile on that or incremental EPS, just trying to model the margin side on Armada correctly. That is it for me. Thanks.

Brian Poff -- Executive Vice President and Chief Financial Officer

Yes. Yes, on Armada, it's $22 million annualized revenue. So we're coming in for two months in Q3 and then you'll see it for full Q4, the margin profile, it's primarily home health, a little bit of hospice, but primarily home health. So those gross margins are nice for us at 40-plus percent. Bottom line margin is going to be somewhere in that kind of mid-teen range as well.

Scott Fidel -- Stephens -- Analyst



[Operator Instructions] Your next question comes from the line of Brian Tanquilut with Jefferies.

Jack Slevin -- Jefferies -- Analyst

Hey. Good morning, guys. Jack Slevin on for Brian. Congrats on a strong quarter. I think we wanted to -- I appreciate all the commentary. I wanted to take a look at the labor side of things in personal care. I guess, just any updates you have on perhaps what the pull-through from your recruitment efforts in May, June, July have been and kind of expectations for top line growth as some of those unemployment -- elevated unemployment benefits roll off as we get into the back half of the year?

Brad Bickham -- Executive Vice President and Chief Operating Officer

Yes, this is Brad. I'll start with talking about the kind of candidate flow we've seen. April, May, a little slower. June was a really good month for us, from both a candidate flow and a hiring standpoint. July numbers actually look good as well. I think what we're seeing on personal care is as these unemployment benefits are starting to -- the enhanced benefits are starting to phase out in various states and then early September entirely.

I think you're starting to see people try to get ahead of that and start applying for jobs. So we're encouraged by the increase in the candidate flow. I think it did bode well for some continued consistent hiring. But as far as on the growth trajectory, I mean, I think we've said the 3% to 5% is the long-term goal, we'll be at the higher end of that range we expect in Q3.

Jack Slevin -- Jefferies -- Analyst

Got it. That's helpful. And then on the hospice business, obviously, I think the challenges are well adjusted and understood in the market. But could you just give a sense of where you're at like maybe July trends on median length of stay and average length of stay? And how you guys are thinking about ADC tracking through the back half of the year?

Brad Bickham -- Executive Vice President and Chief Operating Officer

Yes, it's Brad again. On the hospice side, I mean, what we've been pleased that when we look at where we were at our kind of low point in January, we have had seen a steady increase in median length of stay and a steady increase in ADC each month, that has continued through July as well. And I think our July median length of stay is 21 days.

If you remember -- recall our kind of low point was in January at 15 days. So we're adding about a day a month. And I think heading back up toward our normalized kind of mid- to upper 20s on the median length of stay, which we anticipate that we'll get there kind of -- we certainly have said the back half of the year, and it looks like that trend is continuing.

Jack Slevin -- Jefferies -- Analyst

Got it. Okay. And then last one for me. On some of the Medicare Advantage pilots, I appreciate that probably you don't have to too much data left or collected at this point. But have you seen any uptick in payers that are interested in running more Medicare Advantage pilots in the core personal care business or anything there?

I think we're hearing a lot of chatter on the payer side about nonmedical determinants of health and social determinants of health, those kind of buzzwords are picking up use. So I just wanted to kind of hear your thoughts on what the landscape looks like there and how we could think about the opportunity set rolling forward a couple of years?

R. Dirk Allison -- President and Chief Executive Officer

Yes. We have seen increased interest from a number of our payers in putting together pilot programs to try to determine the effectiveness of personal care inside, say, a Medicare Advantage program or a managed Medicaid program. In fact, we're working on a number of other pilots that we hope to announce over the next few months. And to the point that we're pretty busy. So I would say long term, it bodes very well.

I think that in the interim, what we have to do, a number of our programs are designed to give us the information and to work with our [payers] on whether it be GAAP closures or whether it be on clinical measures such as ER visits and readmissions. And as we get that data -- and we're hopeful that we're starting to see some of that data now.

As we get that data and it continues to be what we expect it to be, then we would think long term, we would be able to show Medicare Advantage plans that by incorporating nonclinical care into their offering, we can overall affect their cost of care. So we're excited about the future, but it's going to take some time. It's not going to happen overnight because a lot of these pilots are just starting, but we're excited about the interest we're seeing.

Jack Slevin -- Jefferies -- Analyst

Awesome. That is it for me. Thanks again and congrats.


Your next question comes from the line of Mitra Ramgopal with Sidoti.

Mitra Ramgopal -- Sidoti -- Analyst

Yes. Hi. Good morning. Thanks for taking the question. I just had a 2-part question on the labor front. First, if maybe you can give us an update in terms of the progress you've made regarding vaccines among your caregivers. And secondly, if that -- with the surge in the Delta variants, et cetera, if that's having an impact in both recruiting and the ability to also bring on new business?

Brad Bickham -- Executive Vice President and Chief Operating Officer

Mitra, this is Brad. On the vaccination front, honestly, we're not where we would like to be overall. We're at about, I think, 35% overall. However, on the skill side, is considerably higher. We're actually a 60-plus percent on the home health side and almost 60% on the hospice side. We're continuing our efforts to educate our caregivers on the benefits of being vaccinated, but it's an ongoing process and certainly more challenging with a personal care workforce that is largely part-time workers.

So just trying to get those individuals vaccinated and also getting honestly good data on that. I mean I think if that 35% is fully vaccinated employees, and it is a little more challenging to pull those numbers through, and I suspect the number is actually higher than that than what we're seeing. With respect to the Delta variants, I really haven't seen an impact yet from the Delta variant, either from standpoint of referral volumes or from employee quarantines, or from affecting the hiring trends yet. So it's something we're certainly mindful of and certainly keeping an eye on. But right now, haven't seen anything material impact on our numbers.

Mitra Ramgopal -- Sidoti -- Analyst

Okay. No. Thanks for that. And just a quick question on the M&A front. Just curious in terms of the valuations you are seeing today, maybe relative to a year ago, if it's there's been a significant change and also just the competitive environment for acquisitions if that's also gotten a little more difficult?

Brian Poff -- Executive Vice President and Chief Financial Officer

Yes, Mitra. I think, on the valuation front, I think in personal care, we really haven't seen much of a change there. I think on the skilled side with a lot of the folks that are trying to kind of enter into the market that we've seen that Dirk was referencing earlier, whether it be through private equity or otherwise, definitely has driven some competition up there.

So [putting] of size and scale and quality, I think you've seen a little bit of a higher multiple being paid, particularly seems in hospice. I think home health, we haven't seen that impact as much. So I think from our perspective, yes, it's an attractive space for a lot of individuals, it's very competitive. If you get in a broker process, this is going to be competitive.

As we've said, I think, a couple of times, we're doing our best to try to do our own sourcing as well to try to maybe avoid some of the situations and not be forced into situations where it's a higher price auction that kind of be in line with our strategy of making sure we're getting good assets that are accretive for Addus and for our shareholders. And I think we've got good opportunities to continue to close those type of deals.

Mitra Ramgopal -- Sidoti -- Analyst

Okay. Thanks for taking the questions.

Brian Poff -- Executive Vice President and Chief Financial Officer

Thank you.


At this time, there are no further questions. I would now like to turn the call back over to Mr. Dirk Allison.

R. Dirk Allison -- President and Chief Executive Officer

Thank you, operator. Thank you, everyone, for your interest in Addus and for being part of our call today. Hope you have a great week.


[Operator Closing Remarks]

Duration: 35 minutes

Call participants:

Dru Anderson -- Corporate Communications

R. Dirk Allison -- President and Chief Executive Officer

Brian Poff -- Executive Vice President and Chief Financial Officer

Brad Bickham -- Executive Vice President and Chief Operating Officer

Matt Borsch -- BMO Capital Markets -- Analyst

Scott Fidel -- Stephens -- Analyst

Jack Slevin -- Jefferies -- Analyst

Mitra Ramgopal -- Sidoti -- Analyst

More ADUS analysis

All earnings call transcripts

AlphaStreet Logo

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Addus HomeCare Stock Quote
Addus HomeCare
$106.34 (-0.80%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.